• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4632503)   Today's Articles (17)   Subscriber (49898)
For: Irie O, Yokokawa F, Ehara T, Iwasaki A, Iwaki Y, Hitomi Y, Konishi K, Kishida M, Toyao A, Masuya K, Gunji H, Sakaki J, Iwasaki G, Hirao H, Kanazawa T, Tanabe K, Kosaka T, Hart TW, Hallett A. 4-Amino-2-cyanopyrimidines: Novel scaffold for nonpeptidic cathepsin S inhibitors. Bioorg Med Chem Lett 2008;18:4642-6. [DOI: 10.1016/j.bmcl.2008.07.011] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2008] [Revised: 07/01/2008] [Accepted: 07/05/2008] [Indexed: 11/17/2022]
Number Cited by Other Article(s)
1
Synthesis, X-ray and Fluorescence Characteristics of Pyrimido[5,4-e]thiazolo[3,2-a]pyrimidine as a Novel Heterocyclic System. J Fluoresc 2017;27:1183-1190. [DOI: 10.1007/s10895-017-2055-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2016] [Accepted: 02/19/2017] [Indexed: 10/20/2022]
2
Ebrahimpour Z, Shiri A, Bakavoli M, Seyedi SM, Bahreini M, Oroojalian F. Microwave-assisted synthesis and antibacterial evaluation of new derivatives of 1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one. HETEROCYCL COMMUN 2016. [DOI: 10.1515/hc-2015-0145] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]  Open
3
3-Quinuclidinol as a nucleophilic catalyst for the cyanation of 2-chloropyrimidines. Tetrahedron Lett 2014. [DOI: 10.1016/j.tetlet.2014.07.033] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
4
Lithiations and Grignard Reactions on Pyrimidine and Quinazoline. ACTA ACUST UNITED AC 2012. [DOI: 10.1007/7081_2012_94] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/13/2023]
5
Azepanone-based inhibitors of human cathepsin S: optimization of selectivity via the P2 substituent. Bioorg Med Chem Lett 2011;21:4409-15. [PMID: 21733692 DOI: 10.1016/j.bmcl.2011.06.045] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2011] [Revised: 06/07/2011] [Accepted: 06/10/2011] [Indexed: 12/31/2022]
6
Lee-Dutra A, Wiener DK, Sun S. Cathepsin S inhibitors: 2004 – 2010. Expert Opin Ther Pat 2011;21:311-37. [DOI: 10.1517/13543776.2011.553800] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
7
6-Phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile as cathepsin S inhibitors. Bioorg Med Chem Lett 2010;20:4350-4. [DOI: 10.1016/j.bmcl.2010.06.072] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2010] [Revised: 06/11/2010] [Accepted: 06/12/2010] [Indexed: 10/19/2022]
8
Cai J, Fradera X, van Zeeland M, Dempster M, Cameron KS, Bennett DJ, Robinson J, Popplestone L, Baugh M, Westwood P, Bruin J, Hamilton W, Kinghorn E, Long C, Uitdehaag JC. 4-(3-Trifluoromethylphenyl)-pyrimidine-2-carbonitrile as cathepsin S inhibitors: N3, not N1 is critically important. Bioorg Med Chem Lett 2010;20:4507-10. [DOI: 10.1016/j.bmcl.2010.06.043] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2010] [Revised: 06/04/2010] [Accepted: 06/05/2010] [Indexed: 10/19/2022]
9
Cai J, Bennett DJ, Rankovic Z, Dempster M, Fradera X, Gillespie J, Cumming I, Finlay W, Baugh M, Boucharens S, Bruin J, Cameron KS, Hamilton W, Kerr J, Kinghorn E, McGarry G, Robinson J, Scullion P, Uitdehaag JC, van Zeeland M, Potin D, Saniere L, Fouquet A, Chevallier F, Deronzier H, Dorleans C, Nicolai E. 2-Phenyl-9H-purine-6-carbonitrile derivatives as selective cathepsin S inhibitors. Bioorg Med Chem Lett 2010;20:4447-50. [DOI: 10.1016/j.bmcl.2010.06.049] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2010] [Revised: 06/07/2010] [Accepted: 06/08/2010] [Indexed: 10/19/2022]
10
Fujii H, Okada K, Ishihara M, Hanamura S, Osa Y, Nemoto T, Nagase H. Hydrogenolysis of the cyclopropyl group into an isopropyl group in the presence of a platinum catalyst and hydrobromic acid. Tetrahedron 2009. [DOI: 10.1016/j.tet.2009.10.064] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
11
Ameriks MK, Axe FU, Bembenek SD, Edwards JP, Gu Y, Karlsson L, Randal M, Sun S, Thurmond RL, Zhu J. Pyrazole-based cathepsin S inhibitors with arylalkynes as P1 binding elements. Bioorg Med Chem Lett 2009;19:6131-4. [DOI: 10.1016/j.bmcl.2009.09.014] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2009] [Revised: 09/02/2009] [Accepted: 09/04/2009] [Indexed: 11/25/2022]
12
Ameriks MK, Cai H, Edwards JP, Gebauer D, Gleason E, Gu Y, Karlsson L, Nguyen S, Sun S, Thurmond RL, Zhu J. Pyrazole-based arylalkyne cathepsin S inhibitors. Part II: Optimization of cellular potency. Bioorg Med Chem Lett 2009;19:6135-9. [DOI: 10.1016/j.bmcl.2009.09.013] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2009] [Revised: 09/02/2009] [Accepted: 09/04/2009] [Indexed: 11/29/2022]
13
Overcoming hERG issues for brain-penetrating cathepsin S inhibitors: 2-Cyanopyrimidines. Part 2. Bioorg Med Chem Lett 2008;18:5280-4. [DOI: 10.1016/j.bmcl.2008.08.067] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2008] [Revised: 08/15/2008] [Accepted: 08/16/2008] [Indexed: 02/08/2023]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA